No Data
No Data
Express News | Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Roth MKM Downgrades Cyclacel Pharmaceuticals(CYCC.US) to Hold Rating
Express News | Cyclacel Pharmaceuticals - Interim Phase 2 Data, Fadraciclib Well Tolerated in Cohort 8 With Common Adverse Events
12 Health Care Stocks Moving In Friday's Intraday Session
Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals Files for Offering of Shares, Warrants
No Data
No Data